Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

A Quintas Cardama, H Kantarjian, D Jones, J Shan, G Borthakur, D Thomas, S Kornblau, S O'Brien and J. Cortes

Blood 113 ( 25 ): 6315 - 6321 , 2009